The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Exploring new treatment avenues has become crucial as mental health challenges such as depression and PTSD continue impacting ...
The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
The Semmelweis reflex occurs when novel ideas are rejected because they challenge existing beliefs. Read on to see how this relates to low-dose ketamine treatment for depression.
Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...